Market Vectors Biotech ETFFund
- Change -1.54 (-1.1%)
- Volume 0.05 M
4:00 PM EDT Apr 24, 2015
U.S. Markets are closed
- Assets $814.9M
- Expense Ratio 0.35%
- Yield N/A
- Vs 50 Day EMA %
- Vs 200 Day EMA %
US Equity ETF
Market Vectors Biotech ETF is an exchange-traded fund incorporated in the USA. The Fund seeks to track the performance of the US Listed Biotech 25 Index.
|TODAY||1 DAY||5 DAY||10 DAY||1 MO||3 MO||6 MO||1 YR||2 YR||5 YR|
Last Close Volume
|AVG VOL (10 D)||CHANGE|
Trend on Last Close
|Price||EMA||EMA P||DATE CROSSED|
03-20-2015 11:59 AM by Todd Shriber
Shares of Biogen Idec (NasdaqGS: BIIB), one of the largest U.S. biotechnology companies, are up 7% Friday and earlier hit an all-time high after the company said an early-stage study revealed its Alzheimer's drug, aducanumab, stemmed cognitive decline in patients compared with th...
03-10-2015 11:00 AM by Todd Shriber
On the heels of last week's news that AbbVie (NYSE: ABBV) will acquire cancer treatments maker Pharmacyclics (NasdaqGS: PCYC) for $21 billion, speculation is abound regarding the next potential takeover targets in the biotechnology industry. The biotech industry and the releva...
03-09-2015 09:30 AM by Todd Shriber
Last week's news that AbbVie (NYSE: ABBV) will pay $21 billion, or $261.25 per share in cash and stock, for Pharmacyclics (NasdaqGS: PCYC), a maker of cancer treatments, in what represents the largest takeover of a biotech company in 15 years underscores a couple of points. Fi...
02-26-2015 05:11 PM by Tom Lydon
By recent standards, Thursday was a docile day for the health care sector, the second-best performer in the S&P 500 this year behind materials. "Just" six healthcare exchange traded funds made new highs Thursday compared with 26 the day before. When six of a sector's ETFs ...
02-11-2015 03:38 PM by Tom Lydon
Healthcare sector exchange traded funds have been outpacing the broader markets and could remain healthy as rising profits diminish concerns over frothy valuations. Over the past year, Health Care Select Sector SPDR (NYSEArca: XLV) rose 25.2% while the SPDR S&P 500 ETF (NY...
02-04-2015 07:30 AM by Todd Shriber
Some well-known biotechnology exchange traded funds could be stirred by Gilead Sciences (NasdaqGS: GILD) fourth-quarter earnings report released Tuesday after the close of U.S. markets. The California-based company posted net income of $3.49 billion, or $2.18 a share, compared...
01-05-2015 08:00 AM by Todd Shriber
Over the last several years, there has rarely been a bad time to own biotechnology exchange traded funds. That much is confirmed by the presence of multiple biotech ETFs on the annual lists of the top 10 sector funds. In 2014, each of the five major biotech ETFs ranked among t...
11-20-2014 09:30 AM by Todd Shriber
Stellar performances by health care stocks and exchange traded funds this year have been well-document and plenty of investors know that the Health Care Select Sector SPDR (NYSEArca: XLV) is the best of the nine sector SPDR ETFs to this point in the year. Up 24.7% year-to-date...
10-23-2014 11:49 AM by Todd Shriber
U.S. stocks appear headed for a fifth consecutive day of gains. While that is good news, the S&P 500's recent winning streak serves as a reminder regarding why October is, historically, the most volatile month of the year. Despite that volatility, biotechnology exchange tr...
10-15-2014 08:00 AM by Tom Lydon
One of this year's sharpest pullbacks in equities was, some market observers would say, attributable to the late first-quarter/early second-quarter retrenchment in biotechnology stocks and the corresponding exchange traded funds. So severe was the aforementioned selloff in bio...
09-03-2014 11:00 AM by Tom Lydon
It was a frequent event in the month of August. Throughout the month, daily checks of exchange traded funds making new all-time highs turned up plenty of health care funds. Much to the chagrin of the biotechnology bears that growled so loud late in the first quarter and early ...
08-20-2014 12:28 PM by Todd Shriber
It seems like only yesterday that there was a cacophony of criticism and doubt from naysayers regarding biotechnology stock and exchange traded funds. In reality, "yesterday" was the first quarter when the usually pricey biotech sector soared to valuations that were double its...
06-28-2014 08:00 AM by Todd Shriber
In a lethargic week for U.S. stocks, investors were seen taking a tactical approach to exchange traded funds. At least that is the anecdotal evidence provided by our weekly look at the most searched ETFs. While broad market ETFs and dividend funds usually occupy several spots ...
06-24-2014 11:36 AM by Todd Shriber
Shares of Vertex Pharmaceuticals (NasdaqGS: VRTX) surged more than 42% Tuesday on volume that is already 11 times above the daily average after the company said two Phase III trials for its cystic fibrosis treatment showed encouraging results. Analysts doubted the ability of V...
05-06-2014 12:46 PM by Todd Shriber
From its Feb. 25 to its April 14 lows, the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) tumbled 21.2%. That fits the definition of a bear market and IBB's decline, along those of the other biotech ETFs, received ample attention due in large part to talk that the biotech se...
04-15-2014 02:36 PM by Tom Lydon
Biotechnology sector exchange traded funds are caught in one of their worst sell-offs, breaking below their long-term trendlines and hovering in bear market territory, as investors dump growth stocks. The largest biotechnology-related ETF, the iShares Nasdaq Biotechnology ETF ...
04-08-2014 12:45 PM by Todd Shriber
It has been said, and it is more often than not true, that flows data for exchange data is not a predictor of future performance, but rather a sign of investors chasing past performance. When it comes to once beloved biotechnology ETFs, it is not debatable that the group's rec...
03-31-2014 02:55 PM by Max Chen
Concern over a global market slowdown and geopolitical risks kept equities markets and stock exchange traded funds relatively unchanged since the start of the year, but the S&P 500 Index is still heading toward its fifth quarterly gain, albeit a small one. The Dow Jones In...
03-21-2014 12:06 PM by Todd Shriber
An oft-discussed theme over the past month has been the decline of biotechnology stocks and exchange traded funds, a conversation that is gaining steam Friday as the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB), the largest biotech ETF, drifts below its 50-day moving average....
02-21-2014 08:15 AM by Todd Shriber
There are five biotechnology exchange traded funds on the market today. Confirming just how strong the sub-sector has been this year three of those ETFs – the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT), the Market Vectors Biotech (NYSEArca: BBH) and the iShare...
01-09-2014 01:57 PM by Todd Shriber
No need to do a double take with the following because it is true: Shares of Intercept Pharmaceuticals (NasdaqGM: ICPT) are up $210, or a tidy 290%, after trials for the company's liver disease treatment proved successful. That is good news for the biotechnology sector, which ...
12-28-2013 08:00 AM by Todd Shriber
Stocks closed flat on Friday, but overall, it was a decent holiday-shortened week for U.S. equities as the S&P 500 managed to tack on almost 0.8% in just 3.5 trading days. While some traders and investors were busy pondering the fate of Twitter (NYSE: TWTR), among other ma...
12-23-2013 08:00 AM by Tom Lydon
This has been, quite simply a very, very good year in which to be long health care exchange traded funds. The Health Care Select Sector SPDR (NYSEArca: XLV) is battling with its discretionary rival to be the best of the nine SPDR ETFs for 2013 and XLV spent some time as the th...
12-19-2013 07:30 AM by Todd Shriber
After several years of struggling and reverse splits in 2012, solar exchange traded funds bounced back with a vengeance in 2013. With the year almost over, the Guggenheim Solar ETF (NYSEArca: TAN) ranks as the year's top-performing non-leveraged ETF, having more than doubled. ...
12-17-2013 02:14 PM by Max Chen
The best performing exchange traded funds this year include some surprise moves and others adding on another stellar year. ETFs that track the solar, alternative energy, broker dealer and biotechnology sectors have outperformed this year, writes Trang Ho for Investor's Busines...
12-17-2013 08:45 AM by Tom Lydon
There is no denying 2013 will go down as a banner year for exchange traded funds with ties to the health care sector. Whether it has been broader plays on the sector such as the Health Care Select Sector SPDR Fund (NYSEArca: XLV) or more focused sub-industry plays like the Mar...
12-10-2013 07:30 AM by Tom Lydon
There are various theories regarding buying a previous year's laggards with the expectation that the new year will bring better results. Call it the "trash to treasure" theory. As is the case with all market theories, last year's rubbish turning to this year's gold is not 100%...
10-31-2013 02:45 PM by Max Chen
Biotech exchange traded funds, market leaders for much of this year, stumbled in October as the government shutdown had an unexpectedly debilitating affect on the high-flying sub-industry. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks large biotech or phar...
10-22-2013 02:24 PM by Todd Shriber
For most of this year biotechnology exchange traded funds have been among the most beloved and top-performing sector ETFs. The recent U.S. government shutdown led to some unexpected retrenchment in a sector previously hailed for proving impervious to macro shocks. While past p...
10-18-2013 11:37 AM by Todd Shriber
Or, in the case of Google (NasdaqGM: GOOG), a quadruple-digit diva. The Internet search giant made it to $1,000, or roughly double the share price of rival Apple (NasdaqGM: AAPL), on the back of a strong third-quarter earnings report. Trading at or around $1,000 is a nice feat...
10-10-2013 07:30 AM by Tom Lydon
Biotechnology exchange traded funds are on a three-day sell-off after falling short of its 52-week high Friday, but the sector can still find its footing. The he iShares Nasdaq Biotech (NasdaqGM: IBB) has declined 7.5% in the past three sessions, Market Vectors Biotech ETF (NY...
10-08-2013 01:14 PM by Tom Lydon
Riding out tax hikes, interest rate risk and geopolitical tensions, the broad equity markets touched historic highs this year, with alternative energy, biotech and technology stock exchange traded funds leading the pack. In the technology space, social media stocks are experie...
10-02-2013 03:00 PM by Gary Gordon
Stocks as an asset class have shrugged off a wide variety of risks throughout the year. Sequestration failed to derail equity enthusiasm. The May-June interest rate spike did little to deter dip-buyers. And I suspect that any actual downside for the markets in October, whether ca...
08-19-2013 04:39 PM by Tom Lydon
The biotechnology sector has been one of the best performing areas in the market this year. While investors can try to bet big, and potentially lose big, on biotech stocks, an exchange traded fund helps diversify risk with a basket of securities. "The jarring pace of change, s...
05-06-2013 04:20 PM by Tom Lydon
Big pharma will soon lose patents on blockbuster drugs, boosting the market for cheap generic drug producers. Too bad there isn't an exchange traded fund that tracks global generic drug makers. The cheap generic drug market could account for $29 billion in total revenue as abo...
12-31-2012 01:32 PM by Tom Lydon
The end of 2012 is here and certain exchange traded funds will close out the year with a bang, while others have hit the market with a thud. Homebuilders rebounded in 2012 beautifully, while commodities just plain underperformed. "This year has proven to be a rather successful...
12-19-2012 10:00 AM by Tom Lydon
Biotechnology exchange traded funds have reaped the performance benefits of merger and acquisition activity and the so-called patent cliff. This sector has produced some of the best-performing ETFs in 2012. "The past few years were particularly tough for small- and mid-cap bio...
12-11-2012 03:30 PM by Tom Lydon
As drug providers shift away from blockbuster drugs, the biotechnology sector, along with related exchange traded funds, will be supported by the next wave of specialized or targeted drugs. For instance, Amgen (NasdaqGS: AMGN) this week announced a deal to acquire genetic sequ...
11-19-2012 03:20 PM by Tom Lydon
Investors got a much-deserved relief rally Monday on hopes the Obama administration and Congress will be able to hammer out a deal to avoid the fiscal cliff before the deadline. In November, the equities market has been weakening as investors pulled out of stocks ahead of the ...
08-13-2012 08:53 AM by Tom Lydon
An exchange traded fund indexed to biotechnology stocks has pulled back about 10% from its all-time reached last month as the sector cools after leading the market higher through much of 2012. Biotech ETFs have been successful in 2012, with some funds returning more than 30% y...
05-14-2012 10:20 AM by John Spence
One sector that has held up very well amid weakness in the overall market is biotech. In fact, ETFs tracking the biotech stocks remain near all-time highs on successful drug trial tests and some investors positioning for deals in the sector. The iShares Nasdaq Biotechnology (N...
05-12-2012 08:45 AM by Tom Lydon
The largest exchange traded fund following natural gas futures was the top gainer in ETFs this week with a 9% rally, stirring hopes that the recovery in natural gas prices is real. Natural Gas. The U.S. Energy Information Administration revealed a smaller-than-expected increas...
04-20-2012 03:09 PM by Tom Lydon
Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash a...
01-19-2012 09:45 AM by John Spence
The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector's largest ETF posting a gain of 20% over the past three months. The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up ...
12-21-2011 07:16 AM by Tom Lydon
Six Merrill Lynch HOLDRS exchange traded securities stopped trading as planned on Tuesday. The funds were officially transferred and changed into Van Eck Global exchange traded funds, and the new funds will begin trading Wednesday. Trading in the biotech, banking, oil services...
11-23-2011 02:44 PM by Tom Lydon
Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch reached an accord on six HOLDRs in August, and now, the transition from the Merrill Lynch HOLDRs to Market Vector exchange traded funds is underway. An exchange offer for the HOLDRS commenced on Nov. 11 an...
08-15-2011 08:26 AM by Tom Lydon
Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch have reached a deal in which Van Eck plans to offer investors in six HOLDRS the chance to swap for shares of new exchange traded funds. Van Eck filed for six sector-specific ETFs with the Securities an...
06-13-2011 01:53 PM by Tom Lydon
Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice. Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday...
04-21-2011 05:55 AM by John Spence
Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug. The data on the drug, BG-12, was "very competitive versus other app...
02-22-2011 02:00 PM by Tom Lydon
While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector. Currently, the bi...
12-21-2010 03:00 PM by Tom Lydon
Economic downturn? What economic downturn? Despite lackluster economic growth, biotechnology exchange traded funds (ETFs) have managed to notch solid performance this year. In the United Kingdom alone, the bioscience sector has exploded. It now includes 942 companies, with 345...
08-08-2010 01:00 PM by Tom Lydon
Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) ...
06-25-2010 01:00 AM by Tom Lydon
Biotechnology has helped improve the lives of many people. Naturally, many biotech stocks boom or bust based on the success of products in their pipeline. But if you're looking for a more diversified and steady approach to biotech investing, look no further than exchange traded f...
06-17-2009 11:00 AM by Tom Lydon
Biotechnology stocks present opportunities, but given the unique challenges of the sector, exchange traded funds (ETFs) may be the better route to go if you're considering making an investment. Owning individual biotechnology companies can be a challenging way to invest in th...
05-12-2009 06:00 AM by Tom Lydon
In the current economic atmosphere, the biotechnology industry and related exchange traded funds (ETFs) are feeling stressed as investment pullbacks have impeded the sector. Ernst & Young posted their annual report, which stated that the recession could force companies to ...
03-24-2009 11:00 AM by Tom Lydon
The biotechnology sector is a place of risky ventures that at times produce lucrative innovations, but the sector and related exchange traded funds (ETFs) need a helping hand in difficult times. Small biotech companies are courting potential buyers, but not many are large enou...
03-12-2009 10:00 AM by Tom Lydon
General Electric (GE) has been stripped of their AAA credit rating by Standard & Poor's, citing troubles within inner-workings,. but exchange traded funds (ETFs) and market are rising above it so far. GE was cited for the poor performance of their finance unit, however, s...
03-10-2009 12:00 PM by Tom Lydon
Will President Barack Obama's decision to lift restrictions on stem cell research be beneficial to the biotechnology industry and its exchange traded funds (ETFs)? This lift on research restrictions will once again allow researchers to use federal funds to work with new cell li...
03-05-2009 12:00 PM by Tom Lydon
President Barack Obama's proposal for health care reform has the biotechnology industry and related exchange traded funds (ETFs) quaking in their boots. Why? This was the industry that seemed relatively immune to the stock market's demise. However, many believe that the Preside...
03-03-2009 10:00 AM by Tom Lydon
Consumers and small businesses may finally get the loans they need, as the Federal Reserve is launching its much awaited $200 billion consumer credit program, although markets and exchange traded funds (ETFs) may need more than that for a sustained rally. TALF. Autos, educati...
02-19-2009 06:00 AM by Tom Lydon
When President Barack Obama put his John Hancock on the $787 billion stimulus package, $140 billion of it was related specifically to fixing health care and, in turn, related exchange traded funds (ETFs). What's in the bill? A provision to help workers who lose their j...
12-11-2008 06:00 AM by Tom Lydon
The ailing economy and credit crisis has taken its toll on the biotechnology industry hurting its stocks and exchange traded funds (ETFs). In an attempt to grab a piece of the pie, the sector is seeking aid from the federal government. On Wednesday, biotech executives plans ...
10-22-2008 06:00 AM by Tom Lydon
Biotechnology, while hurting along with the rest of the market, is one of the few that can boast market outperformance during these tough market times, evidenced in the performance of the related exchange traded funds (ETFs). Billy Fisher for TheStreet points out that while th...
09-03-2008 01:00 AM by Tom Lydon
When it comes to selecting your exchange traded fund (ETF), it doesn't have to be like a box of chocolates. Unlike Forrest Gump, investors do not have to choose an ETF and never know what they are going to get... at least savvy ones don't. Certain ETFs just do not live up t...
07-16-2008 11:00 AM by Tom Lydon
Biotechnology is the non-commodity exchange traded fund (ETF) area du jour, it seems. In a time where the markets seem bleak, the sector is delivering a ray of light. Genentech (DNA) this week upped its 2008 forecast, and also said its second-quarter profit rose 4.7%, thanks t...
07-10-2008 11:00 AM by Tom Lydon
Not many exchange traded funds (ETFs) outside those focused on commodities are perched above their 200-day moving averages. That makes it worth noting that two biotechnology ETFs crossed the mark recently. Both iShares Nasdaq Biotechnology (IBB) and Biotechnology HOLDRs (BBH) ...